A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Cetrelimab (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUEST
- Sponsors Janssen Research & Development
- 27 Dec 2018 Planned number of patients changed from 60 to 150.
- 27 Dec 2018 Planned End Date changed from 31 Dec 2020 to 31 Aug 2021.
- 08 Nov 2018 Planned End Date changed from 31 Mar 2021 to 31 Dec 2020.